4100 John R, Detroit, MI, 48201 · (800) 576-6266
Beds
115
FY 2025
Star rating
3 of 5
Patient survey: 4 of 5
Net patient revenue
$401.6M
FY 2025
Net income
$55.3M
Patient care margin -30.3%
Discharges
2,351
Occupancy 55.6%
Clinicians
324
From the hospital's yearly cost reports (fiscal years as the hospital reports them)
Locations are shown at the center of the ZIP code.
US dollars as reported. Patient care margin = net patient revenue minus operating expenses, before other income such as grants, donations and investments.
| Fiscal year | Net patient revenue | Operating expenses | Patient care margin | Net income | Discharges | Uncompensated care | Medicare days | Medicaid days |
|---|---|---|---|---|---|---|---|---|
| 2025 | $401.6M | $523.1M | -30.3% | $55.3M | 2,351 | $2.2M | 17.5% | 1.2% |
Official hospital quality measures with the national median across hospitals. For ratios, 1.00 means as many cases as expected.
| Hospital-wide death rate within 30 days | 3.4% | US median 3.9% |
| Death rate for pneumonia patients | 16.3% | US median 15.2% |
| Readmission rate for pneumonia | 16.8% | US median 17.2% |
| Serious complications (patient safety composite) | 1.01 | US median 0.96 |
| C. diff intestinal infections (ratio to expected) |
Medicare clinicians who list this hospital, by specialty
Inpatient stays by diagnosis related group (DRG), 2024
Official US government data: hospital records, ownership records, yearly cost reports and quality measures, linked by the hospital's CCN and NPI. Financials are for fiscal years as reported by the hospital.
Medicare clinicians who work here
| 2024 | $396.5M | $480.4M | -21.2% | $64.6M | 2,240 | $1.8M | 21.3% | 0.6% |
| 2023 | $335.6M | $419.2M | -24.9% | $39.7M | 2,176 | $2.8M | 20.6% | 1.1% |
| 2022 | $284.8M | $363.8M | -27.8% | $24.3M | 2,183 | $3.0M | 21.2% | 4.3% |
| 2021 | $271.9M | $337.0M | -23.9% | $20.4M | 2,694 | $1.8M | 20.8% | 3.0% |
| 2020 | $222.2M | $290.3M | -30.6% | $20.5M | 2,660 | $1.8M | 25.7% | 3.3% |
| 0.98 |
| US median 0.28 |
| Central line bloodstream infections (ratio to expected) | 0.78 | US median 0.48 |
| MRSA bloodstream infections (ratio to expected) | 1.33 | US median 0.60 |
| Catheter urinary tract infections (ratio to expected) | 0.00 | US median 0.40 |
| Doctors always communicated well | 80% | US median 79% |
| Nurses always communicated well | 85% | US median 80% |
| Patient survey summary star rating | 4 of 5 | US median 3 of 5 |
| Area around the room always quiet at night | 64% | US median 59% |
| Patients who rated the hospital 9 or 10 out of 10 | 78% | US median 72% |
| Room and bathroom always clean | 68% | US median 73% |
| Patients who would definitely recommend the hospital | 78% | US median 71% |
| Patients prescribed 2 or more opioids or opioids with benzodiazepines at discharge | 13% | US median 15% |
| Patients who got appropriate care for severe sepsis and septic shock | 33% | US median 65% |
| Healthcare workers given the flu vaccine | 75% | US median 79% |
| 17 |
| $526,137.41 |
| $156,006.53 |
| $125,266.48 |
| DRG 837 CHEMOTHERAPY WITH ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS OR WITH HIGH DOSE CHEMOTHERAPY A | 15 | $87,865.47 | $40,094.07 | $50,344.29 |
| DRG 847 CHEMOTHERAPY WITHOUT ACUTE LEUKEMIA AS SECONDARY DIAGNOSIS WITH CC | 13 | $34,630.92 | $10,225.08 | $12,158.78 |
| DRG 164 MAJOR CHEST PROCEDURES WITH CC | 11 | $53,013.45 | $20,078.55 | $20,435.81 |
Hospital outpatient services by payment group (APC), 2024
| Service group | Services | Patients | Medicare pays per service | All hospitals |
|---|---|---|---|---|
| APC 5072 Level 2 Excision/ Biopsy/ Incision and Drainage | 219 | 205 | $1,123.45 | $1,219.56 |
| APC 5372 Level 2 Urology and Related Services | 154 | 56 | $469.18 | $502.15 |
| APC 5073 Level 3 Excision/ Biopsy/ Incision and Drainage | 109 | 85 | $1,957.34 | $2,141.49 |
| APC 5183 Level 3 Vascular Procedures | 106 | 99 | $2,236.72 | $2,405.01 |
| APC 5182 Level 2 Vascular Procedures | 53 | 47 | $1,082.93 | $1,204.32 |
| APC 8011 Comprehensive Observation Services | 51 | 37 | $1,920.76 | $2,090.36 |
| APC 5374 Level 4 Urology and Related Services | 32 | 25 | $2,446.31 | $2,629.24 |
| APC 5373 Level 3 Urology and Related Services | 32 | 26 | $1,429.27 | $1,516.28 |
| APC 5165 Level 5 ENT Procedures | 27 | 26 | $4,109.39 | $4,436.36 |
| APC 5362 Level 2 Laparoscopy and Related Services | 26 | 26 | $7,429.78 | $8,164.45 |
| APC 5302 Level 2 Upper GI Procedures | 24 | 12 | $1,332.16 | $1,444.50 |
| APC 5154 Level 4 Airway Endoscopy | 24 | 22 | $2,627.83 | $2,832.62 |
Reported payments to this teaching hospital
| Company | Payments | Amount |
|---|---|---|
| Genmab U.S., Inc. GMAB | 329 | $2.0M |
| Regeneron Pharmaceuticals, Inc. REGN | 408 | $1.7M |
| AstraZeneca UK Limited AZN | 2 | $1.1M |
| Merck Sharp & Dohme LLC MRK | 28 | $1.1M |
| Janssen Research & Development, LLC JNJ | 219 | $816K |
| Pfizer Inc. PFE | 153 | $642K |
| Celgene Corporation BMY | 7 | $526K |
| AstraZeneca Pharmaceuticals LP AZN | 8 | $363K |
| Genentech, Inc. ROG.SW | 95 | $325K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 146 | $318K |
Official US government data on Original Medicare hospital stays and outpatient services; groups with fewer than 11 cases are not published. Payments are those drug and device companies must report.
Karmanos Cancer Center is a nonprofit short-term acute care hospital in Detroit, MI with 115 beds, part of McLaren Health Care Corporation and a 3-star overall rating.
Karmanos Cancer Center in Detroit, MI has 115 beds (fiscal year 2025 cost report); 123 beds are certified for Medicare. It discharged 2,351 inpatients that year, with 55.6% of its beds in use on average.
In fiscal year 2025 (ending 2025-09-30), Karmanos Cancer Center reported net patient revenue of $401.6M and operating expenses of $523.1M, a margin on patient care of -30.3%. After other income and expenses its net income was $55.3M (9.6% of revenue), so it made a profit that year.
Karmanos Cancer Center is part of McLaren Health Care Corporation, a health system with 12 hospitals based in Grand Blanc, MI. It is a nonprofit hospital.
Karmanos Cancer Center has an overall rating of 3 out of 5 stars in the official hospital quality ratings. Patients rate it 4 out of 5 stars in the patient survey.
No, Karmanos Cancer Center does not list emergency services.
324 Medicare clinicians list Karmanos Cancer Center as a hospital they work at, most often in Internal Medicine, Nurse Practitioner, Certified Registered Nurse Anesthetist (Crna).
In 2024, Karmanos Cancer Center had 110 Medicare inpatient stays in 6 diagnosis groups. The most common was DRG 871 (septicemia or severe sepsis without mv >96 hours with mcc) with 31 stays; Medicare paid $18,152.71 per stay on average, compared with $15,524.21 across all hospitals.
In 2025, companies reported $11.7M in payments to Karmanos Cancer Center as a teaching hospital ($168K general and $11.5M for research) from 44 companies.